Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1203-1211

  Van Duin, David ^a   Cober, Eric ^b   Richter, Sandra S ^b   Perez, Federico ^c,d   Kalayjian, Robert C ^e   Salata, Robert A ^d   Evans, Scott ^f   Fowler, Vance G ^g   Kaye, Keith S ^h   Bonomo, Robert A ^c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e METROHEALTH MEDICAL CENTER   (United States)

^f CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^g DUKE UNIVERSITY   (United States)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycosides; Carbapenem resistant enterobacteriaceae; MDR; Tigecycline; UTIs

Indexed keywords

AMIKACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE URINARY TRACT INFECTION; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TREATMENT FAILURE; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY; MIDDLE AGED; MOLECULAR TYPING; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MOLECULAR TYPING; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84926452597     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku495     Document Type: Article

References (26)

1. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
2. van Duin D, Kaye KS, Neuner EA et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 2013; 75: 115-20.
3. van Duin D, Perez F, Rudin SD et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014; 58: 4035-41.
4. Rasheed JK, Kitchel B, Zhu W et al. NewDelhimetallo-β-lactamase-producing Enterobacteriaceae, United States. Emerg Infect Dis 2013; 19: 870-8.
5. Deleo FR, Chen L, Porcella SF et al. Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci USA 2014; 111: 4988-93.
6. CDC. CDC/NHSN Surveillance Definitions for Specific Types of Infections. http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf.
7. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999; 11: 7-12.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
9. Lascols C, Hackel M, Marshall SH et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 2011; 66: 1992-7.
10. Viau RA, Hujer AM, Marshall SH et al. "Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a longterm care facility for children and young adults in Northeast Ohio. Clin Infect Dis 2012; 54: 1314-21.
11. Diancourt L, Passet V, Verhoef J et al. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J ClinMicrobiol 2005; 43: 4178-82.
12. Ramirez MS, Xie G, Marshall SH et al. Multidrug-resistant (MDR) Klebsiella pneumoniae clinical isolates: a zone of high heterogeneity (HHZ) as a tool for epidemiological studies. Clin Microbiol Infect 2012; 18: E254-8.
13. Wright MS, Perez F, Brinkac L et al. Population structure of KPC-producing Klebsiella pneumoniae from midwestern U.S. hospitals. Antimicrob Agents Chemother 2014; 58: 4961-5.
14. Lavigne JP, Cuzon G, Combescure C et al. Virulence of Klebsiella pneumoniae isolates harboring bla KPC-2 carbapenemase gene in a Caenorhabditis elegans model. PLoS One 2013; 8: e67847.
15. Diago-Navarro E, Chen L, Passet V et al. Carbapenem-resistant Klebsiella pneumoniae exhibit variability in capsular polysaccharide and capsule associated virulence traits. J Infect Dis 2014; 210: 803-13.
16. Robin F, Hennequin C, Gniadkowski M et al. Virulence factors and TEM-type b-lactamases produced by two isolates of an epidemic Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2012; 56: 1101-4.
17. Tsai YK, Fung CP, Lin JC et al. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother 2011; 55: 1485-93.
18. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-50.
19. Zarkotou O, Pournaras S, Tselioti P et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17: 1798-803.
20. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-13.
21. Daikos GL, Tsaousi S, Tzouvelekis LS et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58: 2322-8.
22. Qureshi ZA, Syed A, Clarke LG et al. Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria. Antimicrob Agents Chemother 2014; 58: 3100-4.
23. Satlin MJ, Kubin CJ, Blumenthal JS et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenemresistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55: 5893-9.
24. Alexander BT, Marschall J, Tibbetts RJ et al. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012; 34: 1314-23.
25. 14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007; 35: 1543-53.
26. Van Duin D, Cober E, Richter S et al. Tigecycline therapy for carbapenemresistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 2014; doi:10.1111/1469-0691.12714.